A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19

Keith, Philip; Day, Matthew; Perkins, Linda M.; Moyer, Lou; Hewitt, Kristi; Wells, Adam

doi:10.1186/s13054-020-2836-4

Cited by 151 publications

(160 citation statements)

References 11 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, TPE may not restore immune homeostasis but may rather aggravate immunoparalysis [4]. We agree with the authors that this outbreak should serve as an impetus to investigate therapies targeting the pathways that lead to morbidity and mortality in these syndromes [1]. This does not mean that we have received a signed blank check to start a therapy without deeply reviewing the rationale and the quality of existing data.…”

mentioning

confidence: 80%

“…The points made in the letter are valid and warrant further investigation. The intent of our editorial was not to protocolize the use of TPE in sepsis and/or COVID-19, rather to highlight its potential and to encourage further study [1].…”

Section: Philip Keith Matthew Day Linda Perkins Lou Moyer Kristi mentioning

confidence: 99%

“…We read with interest the recent editorial by Keith et al who concluded that their practice has changed based on their experience, and they now often utilize therapeutic plasma exchange (TPE) earlier in the clinical course of septic shock with multiple organ failure (MODS) and acute respiratory distress syndrome (ARDS) rather than using it as a "rescue therapy" [1]. We would like to make some comments.…”

mentioning

confidence: 99%

“…They quoted several studies, including one from Knaup et al, in order to support their argument [2]. They assert that TPE is unique by offering benefit on multiple levels by removing inflammatory cytokines, stabilizing endothelial membranes, and resetting the hypercoagulable state [1]. Knaup et al stated that a major difference between TPE and modern extracorporeal adsorption strategies is based on the fact that the exchange of septic shock plasma with fresh frozen plasma may not lead to an unselective depletion of pro-and anti-inflammatory cytokines and will rather replenish protective factors (within FFPs) that have been consumed by the sepsis [2].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure

et al. 2020

View full text Add to dashboard Cite

mentioning

confidence: 80%

Section: Philip Keith Matthew Day Linda Perkins Lou Moyer Kristi mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure

et al. 2020

View full text Add to dashboard Cite

“…Meanwhile there a several publications, which show that the renaissance of passive immunization could be a bridging technology until effective medications or an active immunization is available. [2][3][4][5][6][7][8][9][10].…”

Section: Passive Immunizationmentioning

confidence: 99%

The role of passive immunization in the age of SARS-CoV-2: an update

et al. 2020

View full text Add to dashboard Cite

The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.

show abstract

Diagnosis of the right atrial myxoma after treatment of COVID‐19: A case report

Jelodar

Mirzaei

Chenari

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical Message Atrial myxoma is a rare disease but has a broad clinical presentation and complication that involves several systems‐ heart, lungs, brain, and systemic. An interdisciplinary approach is very important to optimize the outcome in patients with atrial myxomas. A thorough examination by primary care providers is crucial. Then radiologists or cardiologists can help with imaging modalities that can help diagnose and characterize the tumor. Prior to surgical resection by cardiothoracic surgeons, patients need to be evaluated by pulmonologists, cardiologists, and anesthesiologists for preoperative risk stratifications. In patients with neurological complications, pulmonary complications, or infectious endocarditis, input from neurologists, hematologists, infectious disease specialists is essential for patient care. In case antiplatelet/anticoagulation therapy or antibiotic treatment is warranted, pharmacists can provide valuable recommendations. Abstract Myxoma is the most common benign cardiac primary tumor, occurring in the right atrium in only 15%–20% of cases. This disease is asymptomatic initially depending upon size of the tumor, and symptoms develop as the tumor spreads. Atrial myxomas are associated with a triad of complications, including obstruction, emboli, and constitutional symptoms (such as fever and weight loss). This regard, embolization of the pulmonary circulation system is a complication of right myxoma. The patient was a 40‐year‐old male who presented to the emergency department complaining of fever and confusion. He had been previously hospitalized due to COVID‐19 and treated with Remdesivir and plasmapheresis. He had tachycardia, tachypnea, thrombocytopenia, and increased liver enzymes. Chest imaging showed nodular lesions with necrotic areas and cavitary lesions in both lungs and the right atrium infected clot was seen in echocardiography. He was treated with intravenous antibiotics and finally underwent heart surgery due to the diagnosis of pulmonary septic embolism. The patient was finally diagnosed with right atrial myxoma according to heart mass histopathology. It is worth noting that the patient's thrombosis had already developed on the right atrial myxoma, which delayed the diagnosis in this patient. This thrombus formation was due to the hypercoagulability state of COVID‐19 and following the insertion of a central venous catheter to perform plasmapheresis as a complication of treatment. Special attention should be paid to thromboprophylaxis and the early diagnosis of intravascular and intracardiac thrombosis in COVID‐19 patients. Furthermore, the use of imaging modalities is recommended to differentiate thrombus from myxoma.

show abstract

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19

Cited by 151 publications

References 11 publications

Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure

Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure

The role of passive immunization in the age of SARS-CoV-2: an update

Diagnosis of the right atrial myxoma after treatment of COVID‐19: A case report

Contact Info

Product

Resources

About